Northern Trust’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.46M Sell
990,646
-136,012
-12% -$709K ﹤0.01% 2518
2025
Q4
$6.93M Sell
1,126,658
-8,907
-0.8% -$64.6K ﹤0.01% 2285
2025
Q3
$8.21M Buy
1,135,565
+176,794
+18% +$1.05M ﹤0.01% 2228
2025
Q2
$5.09M Sell
958,771
-54,785
-5% -$324K ﹤0.01% 2450
2025
Q1
$8.99M Sell
1,013,556
-18,576
-2% -$223K ﹤0.01% 2101
2024
Q4
$14.2M Buy
1,032,132
+64,923
+7% +$1.2M ﹤0.01% 1920
2024
Q3
$26.5M Buy
967,209
+33,288
+4% +$901K ﹤0.01% 1449
2024
Q2
$22.8M Sell
933,921
-22,435
-2% -$492K ﹤0.01% 1470
2024
Q1
$20.4M Buy
956,356
+14,219
+2% +$306K ﹤0.01% 1583
2023
Q4
$18M Sell
942,137
-80,002
-8% -$1.38M ﹤0.01% 1686
2023
Q3
$16.4M Buy
1,022,139
+2,238
+0.2% +$42.6K ﹤0.01% 1685
2023
Q2
$23.6M Buy
1,019,901
+22,706
+2% +$496K ﹤0.01% 1474
2023
Q1
$23.2M Sell
997,195
-12,161
-1% -$247K ﹤0.01% 1460
2022
Q4
$14.6M Sell
1,009,356
-194,425
-16% -$3.62M ﹤0.01% 1748
2022
Q3
$23M Sell
1,203,781
-32,464
-3% -$745K 0.01% 1372
2022
Q2
$22.5M Sell
1,236,245
-7,418
-0.6% -$154K ﹤0.01% 1447
2022
Q1
$31.3M Sell
1,243,663
-41,159
-3% -$1.05M 0.01% 1362
2021
Q4
$35.5M Sell
1,284,822
-1,021
-0.1% -$29.6K 0.01% 1362
2021
Q3
$41.5M Sell
1,285,843
-32,582
-2% -$1.08M 0.01% 1233
2021
Q2
$40.3M Buy
1,318,425
+54,934
+4% +$1.59M 0.01% 1319
2021
Q1
$38.5M Sell
1,263,491
-448,625
-26% -$12.7M 0.01% 1334
2020
Q4
$33.9M Sell
1,712,116
-148,739
-8% -$2.4M 0.01% 1390
2020
Q3
$24.3M Sell
1,860,855
-62,529
-3% -$791K 0.01% 1478
2020
Q2
$21.8M Buy
1,923,384
+33,348
+2% +$474K 0.01% 1548
2020
Q1
$27M Buy
1,890,036
+8,904
+0.5% +$188K 0.01% 1188
2019
Q4
$51.2M Sell
1,881,132
-15,683
-0.8% -$431K 0.01% 1002
2019
Q3
$54.3M Buy
1,896,815
+101,347
+6% +$2.95M 0.01% 903
2019
Q2
$49.9M Buy
1,795,468
+103,590
+6% +$2.93M 0.01% 999
2019
Q1
$56.2M Sell
1,691,878
-201
-0% -$6.12K 0.01% 876
2018
Q4
$49.2M Buy
1,692,079
+34,066
+2% +$1.23M 0.01% 866
2018
Q3
$76.3M Sell
1,658,013
-143,869
-8% -$6.4M 0.02% 704
2018
Q2
$67.3M Buy
1,801,882
+47,994
+3% +$1.62M 0.02% 770
2018
Q1
$51.8M Buy
1,753,888
+102,920
+6% +$3.48M 0.01% 967
2017
Q4
$56.7M Buy
1,650,968
+117,934
+8% +$3.98M 0.01% 892
2017
Q3
$55.5M Buy
1,533,034
+240,446
+19% +$6.86M 0.01% 877
2017
Q2
$33.4M Buy
1,292,588
+306,276
+31% +$6.5M 0.01% 1273
2017
Q1
$18.9M Buy
986,312
+149
+0% +$2.64K 0.01% 1666
2016
Q4
$16.4M Sell
986,163
-32,978
-3% -$597K 0.01% 1741
2016
Q3
$21M Sell
1,019,141
-6,363
-0.6% -$161K 0.01% 1557
2016
Q2
$31.4M Sell
1,025,504
-13,529
-1% -$470K 0.01% 1135
2016
Q1
$38.9M Buy
1,039,033
+12,969
+1% +$489K 0.01% 975
2015
Q4
$44.3M Buy
1,026,064
+25,891
+3% +$1.09M 0.01% 895
2015
Q3
$37.5M Buy
1,000,173
+409,092
+69% +$14.5M 0.01% 991
2015
Q2
$20.1M Buy
591,081
+162,618
+38% +$5.53M 0.01% 1578
2015
Q1
$15.2M Buy
428,463
+6,151
+1% +$220K ﹤0.01% 1787
2014
Q4
$14.4M Sell
422,312
-8,374
-2% -$297K ﹤0.01% 1787
2014
Q3
$16.6M Buy
430,686
+36,833
+9% +$1.37M 0.01% 1647
2014
Q2
$15.3M Sell
393,853
-69,951
-15% -$2.6M ﹤0.01% 1737
2014
Q1
$15.9M Buy
463,804
+52,573
+13% +$1.63M 0.01% 1768
2013
Q4
$8.63M Buy
411,231
+39,359
+11% +$995K ﹤0.01% 2183
2013
Q3
$8.74M Buy
371,872
+13,295
+4% +$378K ﹤0.01% 2109
2013
Q2
$9.64M Buy
+358,577
New +$10.4M ﹤0.01% 1949

Other funds holding MYGN

Northern Trust's MYGN Position: Q1 2026 in Review

Northern Trust reduced its Myriad Genetics (MYGN) stake by 12% in Q1 2026, selling an estimated $709K and leaving 990,646 shares worth $4.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2518.

Northern Trust first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $76.3M in Q3 2018. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Northern Trust held 990,646 shares of Myriad Genetics worth $4.46M as of Q1 2026.
  • Northern Trust sold 136,012 Myriad Genetics shares in Q1 2026, an estimated $709K.
  • Myriad Genetics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2518 holding.
  • Northern Trust first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
  • Northern Trust's Myriad Genetics position peaked at $76.3M in Q3 2018.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.